Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of September 30, 2024, Syros Pharmaceuticals, Inc. has 26.83M shares outstanding.

As of September 30, 2024, Syros Pharmaceuticals, Inc. maintains a current ratio of 2.25, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -541.45, indicating conservative leverage, while an interest coverage ratio of -20.70 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2024. Return on assets (ROA) is negative at -84.04, reflecting losses generated across the asset base. The company generates approximately 5,676.47 in revenue per employee across its workforce of 68.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended September 30, 2024, Syros Pharmaceuticals, Inc. generated 386,000.00 in revenue and converted that into -97.81M in net income, yielding earnings per share of -2.66. EBITDA reached -110.32M, while operating income came in at -111.52M.

As of September 30, 2024, Syros Pharmaceuticals, Inc. holds 58.28M in cash and equivalents against 60.23M in total debt, resulting in a net debt position of -17.19M. Total book value stands at -11.12M, with working capital of 35.54M providing operational flexibility.

Syros Pharmaceuticals, Inc. produced -100.02M in operating cash flow over the twelve months ended September 30, 2024. After subtracting -38,000.00 in capital expenditures, free cash flow totaled -100.05M - equivalent to -2.72 per share.

These figures cover the twelve months ended September 30, 2024. The operating margin of -28,892.23 and net profit margin of -25,340.67 provide insight into operational efficiency.

Syros Pharmaceuticals, Inc.'s most recent stock split took place on September 26, 2022 with a 10:1 split ratio.